High levels of PD-L1, defined as positive staining via immunohistochemistry (IHC) in ≥50% of tumor cells, seem to correlate with an improved response rate to Pembrolizumab and OS compared with low or absent PD-L1 expression [23,24]. Here, CD274 is linked to neoplasm.